Topical formulation for administering a compound

A pharmaceutical ointment formulation, comprising:

• 3% (w/w) of compound I or a pharmaceutically acceptable salt thereof;
• 32% (w/w) polyethylene glycol 4500;
• 39.95% (w/w) polyethylene glycol 400;
• 15% (w/w) dimethyl isosorbide;
• 4% (w/w) water;
• 5% (w/w) polyoxyl stearate 100;
• 1% (w/w) butylated hydroxytoluene;
• and
• 0.05% caramel colorant.

A pharmaceutical ointment formulation, comprising:

• 6% (w/w) of compound I or a pharmaceutically acceptable salt thereof;
• 35% (w/w) polyethylene glycol 4500;
• 33.95% (w/w) polyethylene glycol 400;
• 15% (w/w) dimethyl isosorbide;
• 4% (w/w) water;
• 5% (w/w) polyoxyl stearate 100;
• 1% (w/w) butylated hydroxytoluene;
• and
• 0.05% caramel colorant.

A method of treating cutaneous lupus, comprising topically administering to a subject a pharmaceutical ointment formulation comprising:

• from 0.1% to 10% (w/w) of a compound I having a formula
• or a pharmaceutically effective salt thereof;
• from 15% to 40% (w/w) of a topical base comprising polyethylene glycol having an average molecular weight of from about 3000 to about 8000 daltons;
• from 25% to 50% (w/w) of a water-miscible solvent;
• from 10% to 20% (w/w) of a penetration enhancer;
• from 3% to 15% (w/w) of an emollient;
• from 3% to 9% (w/w) of a surfactant;
• from 0.5% to 1.5% (w/w) of an antioxidant;
• and
• from 0.05% to 0.25% (w/w) of a colorant.